News

Governor Northam Grants $3.4 Million to Advance Research Commercialization

Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the inaugural funding round for CCF, which was developed through the Virginia Innovation Partnership Authority (VIPA).

“Facilitating research breakthroughs and getting new technologies out of the lab and into the hands of consumers is key to driving economic growth and creating jobs in the Commonwealth,” said Governor Northam. “I am confident this first round of CCF awards will produce far-reaching benefits and congratulate these innovators and entrepreneurs on their success in developing transformative solutions to improve lives and address some of the most pressing challenges we face.”

CCF was launched in 2020 to promote innovative and collaborative commercialization efforts, consolidating two legacy programs, the Commonwealth Research Commercialization Fund and the Virginia Research Investment Fund. The Fiscal Year 2021 round offered grants of up to $100,000 to advance early-stage technology projects in strategically important industries through product or service development, market research, intellectual property protection, marketing, pilots, and more. Award recipients will provide 1:1 match funding.

“The new Commonwealth Commercialization Fund signals Virginia’s commitment to increasing commercialization outcomes for small Virginia businesses across many industries,” said Secretary of Commerce and Trade Brian Ball. “Early funding is essential in bringing new products and innovations to market and we look forward to watching the awardees’ innovations thrive in the Commonwealth.”

“We are excited to announce these awards from this first solicitation of CCF,” said Bob Stolle, President of VIPA. “VIPA was created to be a catalyst for expanding innovation and entrepreneurship in Virginia with a clear goal of accelerating scientific, technology-based research and commercialization. These awards are just the beginning of our work with companies, universities, and research institutes to advance research from proof-of-concept to commercialization.”

CCF seeks technologies with a high potential for economic development and job creation and that position the Commonwealth as a national leader in science- and technology-based research, development, and commercialization. For more information about the CCF program, visit cit.org/ccf.

A few companies receiving the CCF projects awards, contingent upon acceptance of award terms and conditions, include:

AgroSpheres, Inc. | Mr. Ameer Shakeel
Commercialization of Reliable, Sustainable Crop Protection Products, $100,000, Agricultural and Environmental Technologies, Charlottesville

BEAM Diagnostics, Inc | Dr. Sarah Snider
Commercialization of Beacon: A Digital Platform for Innovative Prediction Tools in Healthcare, $100,000, Life and Health Sciences, Roanoke

Bonumose, Inc. | Mr. Edwin Rogers
Making Healthy Sugar Affordable for the Mass Market, $100,000, Life and Health Sciences, Charlottesville

Cerillo, Inc. | Mr. Kevin Seitter
Development of a Low-Cost, Miniaturized, Field-Deployable ELISA Reader, $100,000, Life and Health Sciences, Charlottesville

Contraline, Inc | Mr. Kevin Eisenfrats
Development of Market Access Strategy for a Novel Male Contraceptive, $99,998, Life and Health Sciences, Charlottesville

Jeeva Informatics Solutions Inc | Mr. Harsha Rajasimha
Remote Touchless Patient Recruitment and Retention Platform for Clinical Research, $100,000, Life and Health Sciences, Vienna

Meru Biotechnologies | Dr. Daniel Rodenhaver
Development and Commercialization of TruBind Technology for Drug Discovery, $95,850, Life and Health Sciences, Richmond

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep